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Abstract
To identify previously unknown genetic loci associated with fasting glucose concentrations, we
examined the leading association signals in ten genome-wide association scans involving a total of
36,610 individuals of European descent. Variants in the gene encoding melatonin receptor 1B
(MTNR1B) were consistently associated with fasting glucose across all ten studies. The strongest
signal was observed at rs10830963, where each G allele (frequency 0.30 in HapMap CEU) was
associated with an increase of 0.07 (95% CI = 0.06-0.08) mmol/l in fasting glucose levels (P = 3.2
= × 10−50) and reduced beta-cell function as measured by homeostasis model assessment (HOMA-
B, P = 1.1 × 10−15). The same allele was associated with an increased risk of type 2 diabetes (odds
ratio = 1.09 (1.05-1.12), per G allele P = 3.3 × 10−7) in a meta-analysis of 13 case-control studies
totaling 18,236 cases and 64,453 controls. Our analyses also confirm previous associations of
fasting glucose with variants at the G6PC2 (rs560887, P = 1.1 × 10−57) and GCK (rs4607517, P =
1.0 × 10−25) loci.
Blood and plasma fasting glucose levels are tightly regulated within a narrow physiologic
range by a feedback mechanism that targets a particular fasting glucose set point for each
individual1,2. Disruption of normal glucose homeostasis and substantial elevations of
fasting glucose are hallmarks of type 2 diabetes (T2D) and typically result from sustained
reduction in pancreatic beta-cell function and insulin secretion.
However, even within healthy, nondiabetic populations there is substantial variation in
fasting glucose levels. Approximately one-third of this variation is genetic3, but little of this
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heritability has been explained. There is growing evidence to suggest that common variants
contributing to variation in fasting glucose are largely distinct from those associated with
major disruptions of beta-cell function that predispose to T2D. Common sequence variants
in the GCK (gluco-kinase) promoter4-6, and around genes encoding the islet-specific
glucose-6-phosphatase (G6PC2)5,6 and the glucokinase regulatory protein (GCKR)7-9,
have each been associated with individual variation in fasting glucose levels, but have, at
best, weak effects on T2D risk8,10. Furthermore, although there are now over 15 genetic
loci strongly associated with the risk of T2D7,10-14, none shows compelling evidence for
association with fasting glucose in the two genome-wide association scans (GWAS) so far
reported5,6.
MAGIC (the Meta-Analyses of Glucose and Insulin-related traits Consortium) represents a
collaborative effort to combine data from multiple GWAS to identify additional loci that
affect glycemic and metabolic traits. Our genetic studies of fasting glucose levels were
originally organized as four distinct consortia: (i) European Network for Genetic and
Genomic Epidemiology (ENGAGE), combining data from deCODE, Northern Finland Birth
Cohort 1966 (NFBC1966), Netherlands Twins Register/Netherlands Study of Depression
and Anxiety (NTR/NESDA) and the Rotterdam Study; (ii) Genetics of Energy Metabolism
(GEM), a meta-analysis of the Lausanne (CoLaus) and TwinsUK scans; (iii) DFS, involving
the Diabetes Genetics Initiative (DGI), Finland-United States Investigation of NIDDM
Genetics (FUSION) and SardiNIA scans; and (iv) the Framingham Heart Study (FHS).
Details of the ten component studies (n = 1,233-6,479) are provided in Supplementary Table
1 online.
As a prelude to more extensive data-sharing, the four consortia initially exchanged the
identities of between 10 and 20 SNPs prominently associated with fasting glucose in their
individual, interim, meta-analyses (n = 6,479-12,389; Supplementary Table 2 online).
Comparison of these signals revealed three loci with consistent effects on fasting glucose
detected in multiple studies. Two of these represented the previously reported signals in
G6PC2 and GCK. In addition, all four groups independently generated evidence for an
association between fasting glucose and SNPs around the MTNR1B(melatonin receptor 1B)
locus (ENGAGE: rs1387153, P = 2.2 10−17; GEM: rs10830963, P = 7.4 × 10−11; DFS:
rs10830963, P = 2.5 × 10−7 FHS: rs11020107, P = 5.8 × 10−4, for the most strongly
associated SNP exchanged from each analysis). The association signals at all three loci were
confirmed on formal meta-analysis including results from all ten studies, after exclusion of
individuals with known diabetes (rs560887 (G6PC2), P = 1.1 × 10−57; rs4607517), (GCK),
P = 1.0 × 1.0−25; rs10830963 (MTNR1B), P = P 3.2 × 10−50; Table 1, Fig. 1, Supplementary
Fig. 1, Supplementary Table 3 and Supplementary Methods online). Subsequent efforts to
harmonize additional aspects of data analysis strategies (including the additional exclusion,
where necessary, of individuals with fasting glucose measures ≥7mmol/l) had only a
marginal impact on estimates of significance and effect size (Supplementary Table 4 online).
We attempted to refine the location of the MTNR1B association signal by extending the
meta-analysis to all SNPs (genotyped and imputed from the HapMap) within the 1-Mb
region flanking the gene (n = 35,812; 981 SNPs). In all, 30 genotyped and imputed SNPs
showed compelling evidence for association with fasting glucose (P < 10−8). The strongest
signal was detected at rs10830963: the minor (G) allele (frequency 0.30 in HapMap CEU15)
at this SNP was associated with a per-allele increase of 0.07 (95% CI = 0.06-0.08) evidence
for mmol/l in fasting glucose (P = 3.2 × 10−50). Consistent association at rs10830963 was
observed in all ten component GWAS, irrespective of whether this SNP was genotyped or
imputed, and of the genotyping platform (Table 1 and Supplementary Table 1). Repeat
meta-analysis within the region after conditioning on rs10830963 revealed no additional
independent signals of association (Supplementary Note online).
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The strength of the association between rs10830963 and fasting glucose was unchanged
after adjustment for body mass index (Supplementary Table 4). Analyses of fasting insulin
levels as well as indices of beta-cell function (HOMA-B) and insulin sensitivity (HOMA-
IR) estimated by the homeostasis model assessment16 were possible in ~24,000 participants
from the ten studies. These established that the glucose-raising allele at rs10830963 was
associated with reduced beta-cell function (P = 1.1 × 10−15), with no appreciable effect on
fasting insulin or insulin sensitivity (Supplementary Table 5 and Supplementary Note
online).
To determine the impact of variants within MTNR1B on T2D risk, we carried out a large-
scale meta-analysis of 13 T2D case-control samples (18,236 T2D cases, 64,453 controls;
corresponding to an effective sample size of 21,179 unrelated cases and 21,179 unrelated
controls). We combined data from the deCODE13, Rotterdam17, KORA18, FUSION stage
2 (ref. 11) and METSIM10 studies and from several case-control samples from the UK10
with publicly available data from the DIAGRAM consortium (which itself aggregates GWA
data from the WTCCC, DGI and FUSION scans)10 (Supplementary Note). We found
strong evidence that the minor G allele of rs10830963 was associated with increased risk of
T2D (odds ratio = 1.09 (1.05-1.12), P = 3.3 × 10−7; Fig. 2 and Supplementary Table 6
online). The possibility that the fasting glucose association might reflect the inclusion within
the cross-sectional study samples of subjects with undiagnosed T2D can be discounted given
that exclusion of those with either known diabetes, or a fasting glucose ≥7mmol/l had little
impact on the strength of the association signal (Table 1 and Supplementary Table 4).
Although the association with T2D does not, despite large-scale replication efforts, reach the
5 × 10−8 threshold consistent with ‘genome-wide significance’15, it seems highly probable,
given the strong impact of this variant on beta-cell function (Supplementary Table 5), that
this is a genuine effect.
The analyses we performed interrogate only a fraction of common sequence variants in a
given region—it is likely that the causal variant for this locus is yet to be identified. The
SNP with the strongest statistical evidence so far, rs10830963, maps within the single 11.5-
kb intron of MTNR1B but does not seem to disrupt consensus transcription factor binding or
cryptic alternative splice sites. The association signal is bounded by recombination hot spots
defining a ~60-kb interval within which all our strongly associated SNPs lie and the causal
variant is likely to reside. This interval contains the entire coding region of MTNR1B. The
only other nearby genes (the coding regions of which lie well outside this 60-kb region) are
SLC36A4 and FAT3, neither of which are compelling candidates. SLC36A4 encodes a
proton/amino acid transmembrane transporter moderately similar to Rattus norvegicus
lysosomal amino acid transporter 1, and FAT3 encodes a cadherin family member which is
the human homolog of the Drosophila melanogaster FAT tumor suppressor gene.
Ultimately, detailed fine mapping and functional analyses will be required to define the
causal allele(s) and to confirm that this effect is mediated through altered function or
expression of MTNR1B.
The size of the MAGIC dataset also allowed us to examine the G6PC2 and GCK regions in
greater detail than had previously been possible. In the G6PC2 region, rs560887, within
intron 3 of the gene, remained the strongest signal whether or not imputed data were
included (P = 1.1 × 10−57 across all ten studies; Supplementary Fig. 1 online). This is the
same SNP reported in one recent paper5 and is in substantial linkage disequilibrium (LD; r2
= 0.72 in HapMap CEU) with the lead SNP (rs563694) identified in another6. In the GCK
region, rs4607517, which lies 6.6-kb upstream of the gene, was the most strongly associated
SNP (P = 1.0 × 10−25; Supplementary Fig. 1 and Table 1). This SNP is also in strong LD (r2
1 in HapMap CEU) with the GCK promoter SNP (rs1799884) that was featured in previous
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reports4. Repeat meta-analysis after conditioning on the respective lead SNPs revealed no
additional independent association signals at either locus (Supplementary Note).
As with the variant in MTNR1B, the magnitude of the fasting glucose associations for both
these signals was unchanged after adjustment for BMI (Supplementary Table 4). Glucose-
raising alleles at GCK and G6PC2 were associated with reduced beta-cell function
(rs4607517[A], P = 9.8 × 10−6; rs560887[C], P = 1.2 × 10−26; Supplementary Table 5 and
Supplementary Note). However, in line with previous reports4,9, neither signal was
strongly associated with T2D in the large-scale meta-analysis: in fact, the glucose-raising
allele at G6PC2 was weakly associated with reduced T2D risk (rs4607517[A], per-allele OR
= 1.05 (1.00-1.10), P = 0.031; rs560887[C], 0.93 (0.89-0.97), P = 0.0017; Supplementary
Table 6).
We found no influence of the noncoding lead SNPs rs10830963, rs560887 or rs4607517 on
gene expression of MTNR1B, SLC36A4, FAT3, G6PC2 or GCK in genome-wide
expression QTL datasets from lymphocyte-derived cell lines19,20, cerebral cortex21 or
liver22, and no evidence for epistatic effects among the three lead SNPs was observed (P for
two-way interactions >0.19 in each of the seven studies including only unrelated individuals;
interactions were not examined in the other three studies).
MTNR1B encodes one of two known human melatonin receptors23. Although this is the
first study to implicate genetic variation in MTNR1B in the regulation of fasting glucose
levels and predisposition to T2D, this relationship is biologically credible. As well as being
highly expressed in the brain, retina and elsewhere24, MTNR1B is transcribed in human
islets and rodent insulinoma cell lines25, and the translated receptor is thought to mediate
the inhibitory effect of melatonin on insulin secretion26. Melatonin release is characterized
by marked circadian variability and these inhibitory effects on insulin secretion may
contribute to the entrainment of circadian patterns of insulin release27. There is substantial
evidence in human and rodent studies linking disturbances of circadian rhythmicity to
metabolic conditions including diabetes28,29, and overexpression of melatonin receptors
has been observed in islets from individuals with T2D as compared to nondiabetic
controls30. Taken together, these findings suggest that the association with raised fasting
glucose and T2D may be driven by variants that augment expression and/or activity of islet
melatonin receptors.
Our findings bring the number of common variant loci influencing fasting glucose levels to
four, three of which were detected in the present study. Variants in GCKR have a smaller
effect size than the others7,9, and the present study design (based on exchange of a limited
number of prominent signals between component groups) was not well-powered to detect
these. However, subsequent meta-analysis of GCKR variants across all ten study samples
confirms the association with fasting glucose (rs780094, P = 8.5 10−9; Supplementary Table
4). The total variance in fasting glucose now attributable to these four signals is 1.5%,
indicating that additional loci remain to be found3. In comparison with GCK and G6PC2,
variants in MTNR1B seem to have a more marked effect on risk of T2D, the effect size
being comparable in magnitude (OR = 1.09 (1.05-1.12)) to several other T2D-susceptibility
genes recently identified in GWAS10. Thus, although the physiological regulation of fasting
glucose set point and the pathological decline in beta-cell function that characterizes
common forms of T2D generally seem to involve different processes, the MTNR1B finding
suggests that this is not always the case. Not only can the study of diabetes-related
quantitative traits provide an important path to the identification of additional T2D
susceptibility loci, but there may also be opportunities for useful therapeutic overlap.
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Figure 1.
Regional plot of fasting glucose association results for the MTNR1B locus across ten
MAGIC GWAS. Meta-analysis −log10 P values are plotted as a function of genomic
position (NCBI build 35). The SNP with the strongest signal (rs10830963) is denoted by a
blue diamond. Estimated recombination rates (from HapMap) are plotted to reflect the local
linkage disequilibrium structure around associated SNPs and proxies (according to a white-
to-red scale from r2 = 0 to r2 = 1 and based on pairwise r2 values from HapMap CEU). Gene
annotations were taken from the University of California Santa Cruz genome browser.
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Figure 2.
Association of rs10830963 with type 2 diabetes (T2D) in 13 case-control studies.
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